ARTICLE | Company News

Dov, Merck deal

August 9, 2004 7:00 AM UTC

DOVP granted MRK an exclusive worldwide license to develop and commercialize DOV 21,947 for all indications and DOV 216,303 to treat depression, anxiety and addiction. Both of the serotonin, norepinephrine and dopamine uptake inhibitors are in the clinic to treat depression. DOV 21,947 is in Phase I, and DOV 216,303 is in Phase II. ...